Industry Should Prefer Early Collaboration "Agreement" Meetings - Alpert
This article was originally published in The Gray Sheet
FDA's propensity to suggest that sponsors hold non-binding "agreement" meetings in lieu of binding "determination" meetings in their pursuit of agency go-ahead is in industry's best interest, Susan Alpert, director of the Center for Devices and Radiological Health's Office of Device Evaluation, maintained.
You may also be interested in...
FDA Center for Devices and Radiological Health Director David Feigal will serve as Office of Device Evaluation acting director on an interim basis following the scheduled departure of Susan Alpert from the position.
Over 40% of 510(k)-related appeals filed with FDA since January 1993 have been found in favor of the appellant, James Norman, a staffer in the agency's Center for Devices and Radiological Health, reported during the recent Health Industry Manufacturers Association's "Device Submissions Workshop."
Manufacturers should be more aggressive in pressing for their rights under the FDA Modernization Act, Senate Labor and Human Resources Health Policy Advisor Jay Hawkins told the Regulatory Affairs Professionals Society Oct. 28 in Washington, D.C.